FANCB Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Mitomycin C forms DNA crosslinks, thus inhibiting DNA replication and cell division. Since FANCB is involved in DNA repair via the FA pathway, crosslinking agents like Mitomycin C functionally inhibit FANCB by overwhelming the repair mechanism it facilitates. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin induces DNA crosslinks that FANCB is responsible for repairing. Excessive crosslinks can saturate the repair capacity of FANCB, leading to its functional inhibition by overwhelming the FA pathway. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide stabilizes the DNA-topoisomerase II complex, leading to DNA breaks. FANCB's role in DNA repair suggests that increased DNA damage can overwhelm the FA pathway and inhibit FANCB's functionality through excessive substrate. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits DNA topoisomerase I, leading to DNA breaks. Overwhelming DNA damage can saturate FANCB's repair activity within the FA pathway, functionally inhibiting it due to excess DNA lesions. | ||||||
Amsacrine hydrochloride | 54301-15-4 | sc-214540 | 10 mg | $232.00 | ||
Amsacrine intercalates into DNA and inhibits topoisomerase II, leading to DNA cleavage. The resulting increase in DNA breaks can potentially overload FANCB's repair function, directly inhibiting its role in the FA pathway. | ||||||
Teniposide | 29767-20-2 | sc-204910 sc-204910A | 25 mg 100 mg | $73.00 $235.00 | 6 | |
Teniposide, a topoisomerase II inhibitor, increases DNA breaks. As FANCB is involved in DNA repair processes, the abundance of DNA damage can functionally inhibit FANCB by providing more damage than the FA pathway can effectively repair. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, can lead to the accumulation of damaged proteins and may indirectly inhibit FANCB by disrupting proteostasis and cellular homeostasis, affecting the cellular environment FANCB operates within. | ||||||
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $182.00 $275.00 $726.00 | 3 | |
Veliparib, a PARP inhibitor, can lead to the persistence of single-strand breaks which can collapse replication forks and become double-strand breaks, potentially saturating the DNA repair machinery including FANCB, leading to its functional inhibition. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib, another PARP inhibitor, can also lead to an increased load of DNA damage by preventing the repair of single-strand breaks, indirectly inhibiting FANCB by effectively increasing the number of lesions for the FA pathway to repair. | ||||||
Talazoparib | 1207456-01-6 | sc-507440 | 10 mg | $795.00 | ||
Talazoparib is a highly potent PARP inhibitor that traps PARP-DNA complexes, leading to increased DNA damage. This can indirectly inhibit FANCB by amplifying the number of DNA lesions that exceed the repair capability of the FA complex. | ||||||